SUMMARY OF PRODUCT CHARACTERISTICS

NAME OF THE MEDICINAL PRODUCT
Oracort

QUALITATIVE AND QUANTITATIVE COMPOSITION
Triamcinolone Acetonide Topical Paste, 0.1%

Excipients:
Mineral oil, fine gelatin powder, pectin, sodium carboxymethylcellulose, polyethylene.

INDICATIONS AND USAGE
Oracort (triamcinolone acetonide topical paste, 0.1%) is indicated for adjunctive treatment and the temporary relief of symptoms associated with oral inflammatory and ulcerative lesions.

DESCRIPTION
Oracort (triamcinolone acetonide topical paste, 0.1%), contains the corticosteroid triamcinolone acetonide in an adhesive vehicle suitable for application to oral tissues. Triamcinolone acetonide is designated chemically as 9-fluoro-11β, 16α, 17, 21-tetrahydroxypregna-1, 4-diene-3, 20-dione cyclic 16, 17-acetal with acetone. The structural formula of triamcinolone acetonide is as follows:

Each gram of Oracort contains 1 mg triamcinolone acetonide in an emollient dental paste containing gelatin, pectin, and carboxymethylcellulose sodium in a plasticized hydrocarbon gel (a
polyethylene and mineral oil gel base).

**CLINICAL PHARMACOLOGY**
Like other topical corticosteroids, triamcinolone acetonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A.

**Pharmacokinetics**
The extent of absorption through the oral mucosa is determined by multiple factors including the vehicle, the integrity of the mucosal barrier, the duration of therapy, and the presence of inflammation and/or other disease processes. Once absorbed through the mucous membranes, the disposition of corticosteroids is similar to that of systemically administered corticosteroids. Corticosteroids are bound to the plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys; some corticosteroids and their metabolites are also excreted into the bile.

**CONTRAINDICATIONS**
Oracort is contraindicated in those patients with a history of hypersensitivity to the active substance or to any of the excipients; it is also contraindicated in the presence of fungal, viral, or bacterial infections of the mouth or throat.

**PRECAUTIONS**

**General**
Oracort may cause local adverse reactions. If irritation develops, Oracort should be discontinued and appropriate therapy instituted. Allergic contact sensitization with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.

If concomitant mucosal infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of Oracort should be discontinued until the infection has been adequately controlled. If significant regeneration or repair of oral tissues has not occurred in seven days, additional investigation into the etiology of the oral lesion is advised.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, glucosuria, and other adverse effects known to occur with parenterally-administered steroid preparations; therefore, it may be advisable to periodically evaluate patients on prolonged therapy with corticosteroid-containing dental pastes for evidence of HPA axis suppression (see PRECAUTIONS, Laboratory Tests). If HPA axis suppression is noted, an attempt should be made to withdraw the drug or to reduce the frequency of application. Recovery of HPA axis function is generally prompt and complete upon discontinuation of therapy.

Information for the Patient
Patients using topical corticosteroids should receive the following information and instructions:
1. This medication is to be used as directed by the physician or dentist. It is for oral use only; it is not intended for ophthalmic or dermatological use.
2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
3. Patients should report any signs of adverse reactions.
4. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, contact the physician or dentist.

Laboratory Tests
A urinary free cortisol test and ACTH stimulation test may be helpful in evaluating HPA axis suppression.

Carcinogenesis, Mutagenesis, Impairment of Fertility
Animal studies have not been performed to evaluate triamcinolone acetonide for potential to induce carcinogenesis, mutagenesis, or impairment of fertility.

Pregnancy Category C
Teratogenic effects
Triamcinolone acetonide has been shown to induce teratogenic effects in several species. In mice and rabbits, triamcinolone acetonide induced an increased incidence of cleft palate at dosages of approximately 120 μg/kg/day and 24 μg/kg/day, respectively (approximately 12 times and 10 times the amount in a typical daily human dose of Oracort when compared following normalization of the data on the basis of body surface area estimates, respectively). In monkeys, triamcinolone acetonide induced cranial skeletal malformations at the lowest dosage studied (500 μg/kg/day), which was approximately 200 times the amount in a typical daily human dose of Oracort when compared following normalization of the data on the basis of body surface area estimates. There are no adequate and well controlled studies in pregnant women.
However, a retrospective analysis of birth defects among children born to mothers that used drugs of the same class as Oracort (corticosteroids) during pregnancy found an approximately 3 times increased incidence of cleft palate. Oracort should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

**Nursing Mothers**
It is not known whether oral application of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Caution should be exercised when corticosteroid containing dental pastes are prescribed for a nursing woman.

**Pediatric Use**
The safety and efficacy of Oracort in children is unknown. Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's Syndrome than mature patients because of a larger skin surface area to body weight ratio. Administration of corticosteroid-containing dental pastes to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

**Geriatric Use**
Clinical studies of Oracort did not include sufficient numbers of subjects age 65 and older to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

**ADVERSE REACTIONS**
The following local adverse reactions may occur with corticosteroid-containing dental pastes: burning, itching, irritation, dryness, blistering or peeling not present prior to therapy, perioral dermatitis, allergic contact dermatitis, maceration of the oral mucosa, secondary infection, and atrophy of the oral mucosa.

Also, see **PRECAUTIONS** for potential effects of systemic absorption.

**Reporting of suspected adverse reactions**
Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: http://sideeffects.health.gov.il

**DOSAGE AND ADMINISTRATION**
Press a small dab to the lesion until a thin film develops. A larger quantity may be required for coverage of some lesions. For optimal results use only enough to coat the lesion with a thin film. Do not rub in. Attempting to spread this preparation may result in granular, gritty sensation and cause it to crumble. After application, however, a smooth, slippery film develops.
The preparation should be applied at bedtime to permit steroid contact with the lesion throughout the night. Depending on the severity of symptoms, it may be necessary to apply the preparation two or three times a day, preferably after meals. If significant repair or regeneration has not occurred in seven days, further investigation is advisable.

**HOW SUPPLIED**
Oracort (triamcinolone acetonide topical paste, 0.1%) is supplied in tubes containing 5 g of dental paste.
Light, beige, odorless paste with fine gritty texture, having no lumps.

**Storage**
Store below 25°.

**SHELF LIFE**
The expiry date of the products is printed on the package materials.

Shelf-life after first opening: 3 months

**MARKETING AUTHORISATION HOLDER AND MANUFACTURER**
Taro International Ltd.
14 Hakitor St., Haifa Bay 2624761
Israel

**MARKETING AUTHORISATION NUMBER**
Oracort 016-08-24803-21

Revised in December 2020.